Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY12 | Q9H244 | 17/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | CDK1 | P06493 | 2/20 | 0.45 |
| ▸ | IGF1R | P08069 | 2/20 | 0.45 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.45 |
| ▸ | BRAF | P15056 | 2/20 | 0.45 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.45 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.45 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.45 |
| ▸ | JAK1 | P23458 | 2/20 | 0.45 |
| ▸ | CDK2 | P24941 | 2/20 | 0.45 |
| ▸ | AXL | P30530 | 2/20 | 0.45 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.45 |
| ▸ | PTK2B | Q14289 | 2/20 | 0.45 |
| ▸ | SMO | Q99835 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14130826 | 0.92 | P2RY12 (0.53) | P2RY12MEN1CDK1IGF1RFGFR1 | |
| SCHEMBL4723076 | 0.92 | P2RY12 (0.56) | P2RY12MEN1 | |
| SCHEMBL4724451 | 0.92 | P2RY12 (0.53) | P2RY12MEN1SMO | |
| SCHEMBL4765611 | 0.91 | P2RY12 (0.65) | P2RY12MEN1 | |
| SCHEMBL4765245 | 0.91 | P2RY12 (0.54) | P2RY12MEN1 | |
| SCHEMBL4723473 | 0.91 | P2RY12 (0.54) | P2RY12MEN1 | |
| SCHEMBL4723105 | 0.91 | P2RY12 (0.57) | P2RY12MEN1 | |
| SCHEMBL4720829 | 0.90 | P2RY12 (0.58) | P2RY12MEN1 | |
| SCHEMBL4720630 | 0.90 | P2RY12 (0.57) | P2RY12MEN1 | |
| SCHEMBL4724486 | 0.89 | P2RY12 (0.69) | P2RY12MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080176857-A1 | 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors | PFIZER INC. | 2008-07-24 | — | — | US | disclosed |
| EP-1874780-A1 | 4-PIPERAZINYLTHIENO[2,3-D]PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS | Pharmacia & Upjohn Company LLC (US) | 2008-01-09 | — | — | EP | disclosed |
| WO-2006100591-A1 | 4-PIPERAZINNYLTHIENO [2,3-D] PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2006-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176857-A1 | 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors | TBXA2R, P2RY4, PF4 | P2RY12 17/4885MEN1 4451/4885CDK1 451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.